Top Tweets for #scripasks
In #ScripAsks Andreas Lysandropoulos shares insights on long-term data in neuroscience trials highlighting why organizational readiness—not just algorithms—will define the competitive advantage in 2026. https://t.co/f12Ob10MSJ
More from the recent #ScripAsks with @azitrainc COO Travis Whitfill discussing #ClinicalTrials & Regulatory Efficiency #RareDisease #biotech #innovation #precisionmedicine $AZTR
From @Citeline & @PharmaScrip's #ScripAsks - @AlterityT’s CEO David Stamler was featured in What does 2026 Hold for #Biopharma - Part 4: R&D #Innovation - #biotech #biopharma #innovation #ClinicalTrials https://t.co/IQEsvEuE8x
From @Citeline's #ScripAsks - @azitrainc COO Travis Whitfill on #RareDisease $AZTR Read the full article here: https://t.co/bIPwyrv3PT
X
In the second instalment of @PharmaScrip’s annual #ScripAsks series, our CEO, Phil L’Huillier, shares his thoughts on the #funding and #partnering trends that are likely to shape the #biopharma industry in 2025. For more: https://t.co/Ym6O3XDa2d
#Biotech #ThoughtLeadership
Our Executive Director of Clinical Operations, Brendan Doran, offered insights into #clinicaltrial trends the #biopharma industry can expect in 2024 as part of @PharmaScrip's 2024 #ScripAsks series. Read his thoughts on adaptive study designs here: https://t.co/AfoVSXzqie
Our President & CEO @SabrinaDareCEO was featured in two additional installments of @PharmaScrip’s #ScripAsks series focused on both #therapeutic area advances & #DEI in #biopharma. Full articles (subscription required): https://t.co/IM4ZgXnSn8,
https://t.co/ZStJInIh70
This week’s Scrip Asks instalment saw industry executives reflect on steps being made towards increased diversity, equity and inclusion in the Biopharma industry, and how this can be built on in 2023. Read more https://t.co/LYsIv4BT6Q #ScripAsks #Biopharma
Our CEO, Dr. Philip Toleikis, was recently featured in @PharmaScrip’s #ScripAsks. Philip emphasizes the potential importance of ethically-sourced #stemcells in #celltherapy advancements for patients with diabetes, including #T1D. Read his commentary here: https://t.co/IJmxjjy4Oe
Our president & CEO @SabrinaDareCEO shared her outlook for #clinicaltrial trends for the year ahead in @PharmaScrip’s recent #ScripAsks series. Read more at https://t.co/Sa8zt0Bpay (a subscription is required).
In the latest #ScripAsks, industry stakeholders shared their predictions around the impact of #ArtificialIntelligence on #biopharma: https://t.co/r1YIHSlTik. Geraldine O'Keeffe, @eqt , Søren Møller, @novoholdings, Chris Hollowood, @SynconaLtd , Stephan Christgau and Eir Ventures.
Scrip Asks… What does 2023 hold for #Biopharma?
More than one hundred industry executives and experts provided insight into what to expect for the year ahead. Here’s what we’ve read so far… Read our article here: https://t.co/SJfrWHiMAB #ScripAsks
Our CEO, Dr. Philip Toleikis, was featured in @PharmaScrip’s #ScripAsks, sharing his thoughts about the future of #biopharma and the advancements of cell therapy to treat chronic diseases, including #T1D. Read his commentary here: https://t.co/erzDpvtU4Q
Our Chief Strategy Officer, Atul Deshpande, was recently featured in the @PharmaScrip Asks Series, sharing insights on how the #biopharma funding environment will evolve in 2023: https://t.co/G7NHiJG8wf #ScripAsks
In the latest of @Scrip’s #ScripAsks… series, our CEO Kevin Lee and CTO Michael Skynner provide their perspectives on what 2022 holds for #biopharma. Read their comments on learning to live with #COVID19 and the latest discoveries in #oncology, here: https://t.co/xeyeexuold
Cullinan CEO Nadim Ahmed spoke to @PharmaScrip about the future of #oncology therapy development and the momentum being built toward effective therapies for difficult-to-treat cancer populations. Check it out here: https://t.co/7VuHZkq51N #ScripAsks
Happy #2022! In the new edition of #ScripAsks, @PharmaScrip examined the latest trends and outlook coming out of 2021 into the next few years for #biotech and #medtech. Our CEO Jim Gabriele shared his insights into data and #AI use.
Read more:
https://t.co/TccO8jTO48
Our president & CEO Marcio Souza was featured in @PharmaScrip’s #ScripAsks series sharing his expectations for 2021. Learn more about his thoughts and optimistic outlook for the #biotech industry.
Part 4 - https://t.co/9vh4l7J6On
Part 5 - https://t.co/RG65OZNgTE
.@PharmaScrip's fourth installment in its #ScripAsks series focuses on #decentralizedclinicaltrials, an area in which @PeytonRHowell expects to see an increase in adoption. https://t.co/9QyqcwVgBp #PharmaScrip
$VCEL CEO Nick Colangelo in #ScripAsks... What's The Current Climate For Deal-Making? https://t.co/GHnHKheBYT @PharmaScrip
Last Seen Hashtags on Sotwe
somno()********** +filter:native_video
Seen from Netherlands
Mangkir
Seen from United States
IdeaVera
Seen from United States
momsonn
804Meetup
Seen from Turkey
hermana taboo
Seen from Ecuador
KreamIggyTygaAtVMAs
Seen from United States
MountainRegionEvent
Seen from United States
バツイチパパの日常
Seen from Brazil
Teen #pussy
Seen from South Africa
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
113.8M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.6M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.7M followers
Taylor Swift
@taylorswift13
83.6M followers
Lady Gaga
@ladygaga
75.1M followers
Virat Kohli
@imvkohli
72.8M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.8M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.7M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers